Immutep IMMP
NASDAQ IMMP
$3.86 +0.26 (+7.08%)
As of: Nov 12, 2026 · 10:06 AM EST

Immutep (IMMP) Return on Sales [ROS] (2014 - 2017)

Updated

Immutep (IMMP) reported Return on Sales [ROS] of -545.26% for the year ended Jun 30, 2026, up 49.74 percentage points from -595.00% a year earlier.

Analysis

Immutep (IMMP) Return on Sales [ROS] (2014 - 2017) Analysis & Trends

Dating back to the year ended Jun 30, 2010, Immutep's Return on Sales [ROS] record includes 13 years.

  • Return on Sales [ROS] has a four-year change of +18415.48 percentage points (years ended Jun 2022 to Jun 2026).
  • The figure for the year ended Jun 30, 2026 ranks as the highest annual Return on Sales [ROS] since the year ended Jun 30, 2020.
  • According to Business Quant data, Return on Sales [ROS] came in at -595.00% in the year ended Jun 30, 2025 and -18960.74% in the year ended Jun 30, 2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 34.46%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 24.35%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 36.01%
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 30.74%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 29.12%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 35.79%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 41.71%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 32.98%
10 Immutep 252.65 Mn 41.62 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2017 -370.98%
Mar 31, 2017 -137.35%
Jun 30, 2016 -1,605.41%
Mar 31, 2016 -763.62%
Jun 30, 2015 -19,635.70%
Jun 30, 2014 -83,682.43%
API Access

Immutep Return on Sales [ROS] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=IMMP&period=max&api_key=YOUR_API_KEY